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ABSTRACT 
Rosuvastatin calcium is a BCS class II drug (low solubility and high permeability), used as a lipid lowering agent by acting as HMG 
CoA reductase inhibitor and it is used for the management of hyperlipidemia. Increase in the solubility of the poorly water soluble 
drug is the most challenging aspect for various new chemical entities which leads to the unsatisfactory dissolution profile, 
consequently, the bioavailability. There are various techniques to enhance the solubility of the drug, such as particle size reduction, 
nanosuspension, use of surfactants, salt formation, pH modifier, solid dispersion etc. Solid dispersions in water-soluble carriers have 
attracted considerable interest as a means of improving the dissolution rate and hence possibly bioavailability, of a range of 
hydrophobic drugs.Carriers are the major players in these formulations, e.g., hydroxypropylmethylcellulose, ethyl cellulose, methyl 
cellulose, polyvinyl pyrrolidone, polyvinyl alcohol etc. HPMC and EC is one of the most efficient polymers among all of these to 
work as a carrier for these drugs to enhance solubility. Four ratios of drug: Carriers were prepared (1:1, 1:3, 1:5, 1:7) and 1:7 was the 
optimized ratio which shows a maximum release of the drug via dissolution profile. In the present work, Solid Dispersions were 
prepared by Kneading technique to enhance the solubility of Rosuvastatin Calcium. Solid dispersions were evaluated for Fourier 
transform infrared spectroscopy (FTIR), thermal analysis, dissolution studies, powder X-ray diffraction (PXRD), scanning electron 
microscopy (SEM), and stability studies to confirm enhancement in solubility. The prepared solid dispersions are formulated into 
tablet dosage form and characterized by various parameters i.e. weight variation, hardness, friability, disintegration, and dissolution 
rate. The evaluated parameters of tablet dosage form show increase in solubility and dissolution rate of the pure drug. 
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INTRODUCTION 
Oral bioavailability of a drug depends on its solubility 
and dissolution rate, and dissolution rate may be rate 
determining step for appearance of medicinal effect, 
therefore need to be increased the dissolution of drug 
with limited water solubility is often needed. Various 
methods are used to improve these characteristics, 
including salt formation, micronization and addition of 
solvent or surface active agents. Solid dispersion (SD) is 
one of the suitable method in which the dispersion of 
one or more active ingredients in an inner carrier or 
matrix in solid state prepared by melting, dissolution in 
solvent or melting solvent method. The Important 
phenomenon in pharmaceutical formulations form is 
solubility and dissolution which plays a vital and 
significant role in pharmaceutical dosage form. 
“Solubility’ is defined as maximum amount of solute 
that can be dissolved in a given amount of solvent” and 
dissolution is defined as a process in which a solid 
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substance solublised in a given solvent i.e. mass transfer 
from the solid surface to the liquid phase. 
1, 2, 3, 4 
Orally administered solid dosage form i.e. tablet or 
capsule, should be released from the dosage form and 
dissolved in the gastrointestinal fluids before it can be 
absorbed and therefore, the oral bioavailability of 
different poorly water soluble drugs is limited by their 
dissolution rates which is  the amount of solid substance 
that goes into solution per unit time under standard 
conditions of temperature, pH and solvent composition 
and constant solid surface area, and increase in the 
dissolution of poorly water soluble drugs by using solid 
dispersion techniques presented a challenge to the 
formulation scientists.
5,6
 
The concept of solid dispersions was originally 
proposed by (Sekiguchi and Obi) solid dispersion 
represents a useful technique for increasing the 
solubility, dissolution and improves the therapeutic 
efficacy of drugs. The term solid dispersion refers to a 
group of solid products consisting of at least two 
different components, i.e. a hydrophilic matrix and a 
hydrophobic drug. The most diffrent hydrophilic carriers 
used for solid dispersions include polyvinylpyrrolidone 
(Povidone, PVP), polyethylene glycols (PEGs), 
hydroxyl propyl methyl cellulose, ethyl cellulose and so 
on. 
7, 8, 9
 
Rosuvastatin (RST) is a crystalline, poorly water soluble 
drug and therapeutically HMG-CA reductase inhibitor. 
Currently, using as a potent lipid lowering agent and 
hypolipidemic agent. Clinically, in some cases it is also 
used in osteoporosis, benign prostatic hyperplasia and 
Alziemer’s Disease. It is having 20% oral bioavailability 
and its t1/2 will be 19 hours. Therefore, the aim of the 
present study is to enhance the solubility and dissolution 
of pure drug by using solid dispersion technique and 
formulated into tablet dosage form. 
10, 11
 
MATERIALS AND METHODS 
Materials 
Rosuvastatin calcium is lipid lowering agent, drug gifted 
by (Biocon Pvt Ltd. Banglore, India), HPMC and Ethyl 
Cellulose used as a polymer by (S.D Fine Chemicals, 
Mumbai), Ehanol used as a sovent by (Balaji Drugs, 
Changshiu Yangyuan. China), Methanol is also a 
solvent by (S.D Fine Chemicals. Mumbai), Lactose is 
used as a diluents and Talc is used as glidant by(S.D 
Fine Chemicals.Mumbai) and Magnesium stearate is 
used as Lubricant  supplied by (National Chemicals. 
Mumbai). All chemicals were of analytical or technical 
grade and were used without further treatment. 
Methodology 
12, 13, 14
 
Preformulation studies 
Pre-formulation studies on active pharmaceutical 
ingredients (API), inactive ingredients (Excipients), and 
their combinations were carried out to finalize 
specifications of active pharmaceutical ingredients, to 
study the chemical compatibility between active and 
inactive ingredient, FTIR studies for Rosuvastatin, 
Hpmc and Ethylcellulose were carried out by weighing 
approximately 1-3 mg of the sample and 0.1 g of 
previously dried potassium bromide. Carefully grind the 
mixture and place the homogeneous mixture in an IR 
pellet die. The KBr disks were prepared by compressing 
the powder. The scanning range was kept from 4000–
450 cm
-1
. The flow properties like bulk density, tapped 
density, compressibility index and hausners ratio were 
determined by using tapped density tester and flow 
characteristics were determined by using angle of repose 
method to evaluate the flowability of the drug and 
excipients blend. 
Melting Point Determination 
The melting point of the Rosuvastatin Calcium was 
determined by capillary fusion method. A capillary 
sealed at one end was filled with small amount of drug 
and the capillary was kept inverted i.e. sealed end down 
words into the melting point apparatus. 
Determination of Absorption Maxima (λ max) 
The absorption maxima of the drug was determined by 
scanning (10μg/ml) solution of drug in methanol 
between 200-400nm by UV spectroscopy. 
Determination of Solubility 
Solubility studies were carried out according to the 
method reported by Higuchi and Connors. Pure drug 
sample dissolved in 10 ml of distilled water and was 
shaken in rotary shaker for 24 hours. After shaking, the 
solution was filtered and their absorbance by 
UVspectroscopy 
Preparation of Standard Curve in Phosphate Buffer 
(pH 6.8) 
Preparation of phosphate Buffer (pH 6.8) 
Take 28.80gm of disodium hydrogen phosphate and 
11.45 gm of Potassium dihydrogen phosphate in 
sufficient water to produce 1000ml. 
Preparatrion of Standard plot 
50mg of drug dissolved in small amount of methanol 
and dilute to 100ml with phosphate buffer pH 6.8, 50ml 
of this solution was taken and dilute to 100ml with 
phosphate buffer pH 6.8 to prepare stock solution of 250 
µg/ml. From this solution take 0.1, 0.2, 0.3, 0.4, 0.6 and 
0.8ml and transferred it into 10 ml volumetric flask and 
volume make upto 10 ml with phosphate buffer and take 
absorbance at 241 nm using phosphate buffer as blank. 
Preparation of binary system of solid dispersion by 
Kneading method 
The pure drug sample and different polymers were 
weighed accurately in different ratios and kneaded for 
30min and add the ethanol:water(1:1) solution into the 
pastle and mortar. The prepared mixture dried in hot air 
oven and after drying and pulverized the mixture screen 
from Sieve no.60 and stored in the airtight container for 
further.  
Characterization of Solid Dispersions 
The prepared solid dispersions were evaluated for 
percent drug content, solubility studies, Fourier 
transform infrared (FTIR), Differential scanning 
calorimetry (DSC), SEM (Scanning electron 
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microscopy),X-ray diffraction (XRD), in vitro drug 
release and dissolution efficiency. 
Determination of Drug Content 
10mg of drug: polymer was accurately weighed and 
transferred to 10ml volumetric flask and volume was 
made up to the mark with pH 6.8 phosphate buffer and 
determine the absorbance at 241 nm by using organic 
solvent as blank. The drug content of Rosuvastatin was 
calculated using standard curve. 
In vitro Drug Release  
In-vitro dissolution of Rosuvastatin solid dispersions 
were studied in USP dissolution apparatus (Electro lab) 
employing a basket stirrer. 900 ml of phosphate buffer 
of pH 6.8 was used as dissolution medium at 50 rpm. 
The temperature of 37 + 0.5°C was maintained 
throughout the experiment. Solid dispersions equivalent 
to 10 mg of RST was used in each test. 5 ml of sample 
of dissolution medium were withdrawn by means of 
pipette fitted with pre-filter at known intervals of time 
and analyzed for drug release by measuring the 
absorbance at 241 nm after suitable dilution with 
phosphate buffer. The volume withdrawn at each time 
interval was replaced with fresh quantity of dissolution 
medium. The amount of RST released was calculated 
and plotted against time and compared with pure drug. 
Fourier Transform Infrared (FTIR) Spectroscopy. 
Fourier Transform Infrared (FTIR) spectra of pure drug, 
HPMC and EC, physical mixture and solid dispersion 
were determined on samples prepared in potassium 
bromide (KBr) disks. Samples were prepared in KBr 
disks by means of a hydrostatic press. The scanning 
range was 400 to 4000 cm
–1
 and the resolution was 4 
cm
1.
 
Differential Scanning Calorimetry (DSC)  
The samples (5 mg each) were placed into pierced 
aluminum container. The studies were performed under 
static air atmosphere in the temperature range of 20°C to 
400°C at a heating rate of 10°C/min. 
Powder X-Ray Diffraction (XRD) Analysis 
The X-Ray Diffraction (XRD) study of pure drug, 
HPMC and EC solid dispersion were recorded using X-
ray diffractrometer. Target CuKa monochromatized 
radiation, voltage 40KV, and current 40mA at ambient 
temperature and data were collected by using scan mode 
a step size of 0.010 at 20/s . 
Formulation of Blends 
15, 16, 17
 
Rosuvastatin calcium: HPMC: EC solid dispersion and 
excipients i.e., Lactose were co-grounded in pestle 
mortar (except talc and magnesium stearate) and were 
passed through mesh. No.60 and finally talc and 
magnesium stearate were added and mixed for 5 
minutes and prepare the powder dosage form. 
Bulk Density  
Bulk density is defined as the mass of powder divided 
by the bulk volume and is expressed as g/cm3 and bulk 
density was calculated using the formula.                 
  ρb= M/Vb                                        eq. no(1) 
where ρb = apparent bulk density, M=weight of powder 
and Vb =bulk volume 
Tapped Density 
It can be defined as mass of blend in the measuring 
cylinder divided by its tapped volume. The measuring 
cylinder containing a known mass of blend was tapped 
100 times using density apparatus. The tapped density 
was calculated using the formula. 
      ρt= M/Vt                                          eq. no(2) 
where Vt=minimum volume and M =weight of the blend  
Compressibility Index 
The simplest way for measurement of flow of powder is 
its compressibility, an indication of the ease with which 
a material can be induced to flow is given by 
compressibility index (I) which is calculated as follows: 
 I= ρt- ρb/ ρt× 100                       eq. no(3) 
Where, ρt = Tapped density, ρb = Bulk density 
Hausner Ratio 
Hausner ratio (HR) is an indirect index of ease of 
powder flow. It is calculated by the following formula 
Hr= ρt/ ρb                                 eq no.(4) 
Where, ρt is tapped density and ρb is bulk density. 
Lower Hausner ratio (<1.25) indicates better flow 
properties than higher ones (> 1.25). 
Angle of Repose  
Angle of Repose was determined using funnel method. 
The blend was poured through a funnel that can be 
raised vertically until a specified cone height (h) was 
obtained. Radius of the heap (r) was measured and angle 
of repose (θ) was calculated using the formula. 
Tan θ=h/r                               eq no.(5)   
 Therefore θ=tan
-1
(h/r) Eq no. (5)   
Tablet Preparation method 
Wet granulation method 
It is the most common and widely used method. This 
method involves various steps like weighing of 
ingredients, mixing, granulation, screening of damp 
pass, drying, lubrication and compression of tablets. The 
main active ingredient, diluents, disintegrants are 
blended together, then it is allowed to pass through the 
sieve (sifting). Solutions of the binding agent are added 
to the initial mixture with stirring. The amount of 
binding agent added should be sufficient, in order to 
avoid over wetting of the tablet. If the powder is not 
wetted properly, the granules will be too soft and can be 
broken down during lubrication, which is difficult 
during compression of tablet. After drying the granules, 
they are allowed to pass through the screen; usually 60-
100 mesh nylon cloth is used. After dry granulation, 
lubricant is added as fine powder, which is required for 
proper filling of the die cavity. 
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Evaluation Parameters of Tablet Dosage Form 
 
General appearance  
It includes overall appearance of the tablet like size, 
shape, odor, taste, color, surface, consistency, textures 
physical flaws. Tablet thickness should be controlled 
with ± 5% variation of standard value. 
Weight variation test 
Twenty tablets were weighed accurately and the average 
weight of the tablet is determined. As per the IP 
specification, if the tablets weight is:   
Table 1: Showing Weight variation test 
 Weight ot Tab(mg)  Acceptance criteria 
<80 10% 
 80-250 7.5% 
 >250 5% 
 
If any tablet deviates from the specification, another 10 
tablets are selected from the batch and the same 
procedure is repeated. In case of 30 tablets, not more 
than one tablet should deviate. 
Hardness test 
It is defined as the force required breaking the tablet. 
Ten tablets from each batch were selected and hardness 
was measured using Digital hardness tester to find the 
average tablet hardness or crushing strength. Hardness 
should be in between 3-6 kg/cm2.   
Friability test 
The friability values of the tablets were determined 
using a Roche friabilator. It is expressed in %. 20 tablets 
were initially weighed (initial weight) and transferred to 
friabilator. Friabilator was operated at 25 rpm for 4 min. 
Percentage friability was calculated using the following 
equation. Friability of tablets less than 1% was 
considered acceptable.   
             
                         
              
                 
Disintegration test  
It is defined as the breakdown of tablet into finely 
divided particulates or granules in GI tract. Six tablets 
were taken randomly from each batch and placed in 
USP disintegration apparatus baskets, which is 
repeatedly immersed 30 times per minute into a 
thermostatically controlled fluid at 37°C and observed 
over the time described in the individual monograph.  
In vitro-dissolution studies 
The release rate of Rosuvastatin calcium l tablets was 
determined using USP Dissolution Testing Apparatus II 
(Paddle type). The dissolution test was performed using 
900 ml of Phosphate buffer pH 6.8, at 37 ± 0.5°C and 
speed of 50 rpm. Aliquot (5 ml) of the solution was 
collected from the dissolution apparatus for every 10min 
and were replaced with fresh dissolution medium. The 
aliquots were filtered through whatmann filter paper 
no.41. Absorbance of these solutions was recorded at 
241nm (Rosuvastatin calcium) in photometric mode. 
Aliquots were withdrawn at ten minute interval from a 
zone midway between the surface of dissolution 
medium and the top of rotating paddle not less than 1 
cm apart from the vessel wall. 
Stability Studies 
Accelerated stability studies were performed on 
prepared solid dispersion tablet dosage form in amber 
colored screw capped bottles and were checked as per 
ICH guidelines at 40%+2
o
Cand 75%+5%RH up to one 
month. The tablets were kept in stability chamber. 
Sample were removed at regular intervals as initial, 7 
days, 14 days, 21 days and 30 days and were analyzed 
for physical characterization, content uniformity and in 
vitro dissolution studies. The similarity factor (f2) was 
used as a basis to compare dissolution profiles. The 
dissolution profiles are considered to be similar when f2 
is between 50 and 100. The dissolution profiles of tablet 
formulations before and after stability testing were 
compared using a similarity factor (f2) which is 
calculated from the following formula: 
 
RESULTS AND DISCUSSION 
Preformulation Studies:  
1) FTIR of pure drug 
 
Figure 1: FTIR of Rosuvastatin Calcium 
2) Melting point determination by Dsc 
The DSC of the pure drug sample as shown below in 
figure 2       
      
 
Figure 2: DSC thermogram of Rosuvastatin Calcium 
3) Absorption Maxima 
Absorption maxima (λ max) of Rosuvastatin Calcium 
were observed in different solvents 
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Table 2: Absorption maxima (λmax) of the Rosuvastatin 
Calcium in different solvent 
Solvent (λmax)nm 
Phosphate buffer 241nm 
Water 240nm 
Methanol 239nm 
 
4) Solubility 
The solubility studies of Rosuvastatin Calcium were 
determined in different solvents.                         
Table 3: Solubility of Rosuvastatin Calcium in different 
solvents 
Solvent Solubility 
Water 1.648±0.326  
Methanol 2.668±0.122 
Phosphate buffer 4.026±0.554 
Data Expressed as mean ± S.D (n=3) 
Solubility of the Rosuvastatin Calcium found to be 
higher in phosphate buffer as compared to other 
solvents. 
5) Drug Excipients Compatibility Studies by FTIR 
Physical mixtures of both pure drug and excipients 
(HPMC and Ethyl Cellulose) were prepared and no 
major changes were observed like discoloration, 
liquefaction between drug and polymer and no odor of 
the physical mixture was found and its compatibility 
studies as shown in the given IR spectra in figure 3 
 
Figure 3: IR Spectra of Mixture of Drug & HPMC: EC 
Standard plot of pure drug 
The calibration curve of Rosuvastatin Calcium was 
found to be linear in the concentration range of 2.5-15 
μg/ml at 241 nm in Phosphate buffer (pH 6.8).The 
absorbance at different concentrations is represented in 
figure 4 respectively. 
 
Figure 4: Standard plot of Rosuvastatin Calcium in 
Phosphate Buffer (pH6.8) 
Characterization of Solid Dispersions 
1) Percent yield and drug content  
The percent yield and drug content of pure drug and 
different solid dispersions were determined and % yields 
decreases at the higher concentrations due to the 
difficulty in sieving due to higher polymer and 
surfactants concentration.  
Table 4: Percent yield or drug content of solid 
dispersions ROS/HPMC: EC 
                              Data Expressed as mean ± S.D (n=3) 
 
 
2) In vitro dissolution studies  
 
Figure 5: %Drug release of pure drug and solid dispersion vs time 
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Time (min) 
Pure 
Drug 
RS 1 
RS 2 
RS 3 
RS 4 
Formulation Code Percentage 
yield 
Drug 
content 
RS1 (1:1) 79.46±0.056 97.89±0.025 
RS2 (1:3) 81.39±0.089 96.55±0.069 
        RS3 (1:5)  83.77±0.126 98.94±0.088 
RS4(1:7) 85.56±0.155 99.59±0.064 
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3) FTIR 
The IR Spectra of Rosuvastatin Calcium and optimized 
solid dispersion as shown in figure 6 and wave number 
is similar with the IR spectra of pure drug and change 
in the wave no. in the IR is  due to the change in the 
hydrogen bonding and C-H  bending and stretching 
vibration of the prepared solid dispersion.
 
 
Figure 6: FTIR of Optimized batch of solid dispersion 
4) Differential Scanning Spectroscopy 
The DSC thermogram of Optimized solid dispersion 
shows no peaks in the diffractogram that indicates the 
change in the nature of drug from crystalline to 
amorphous form and reduces with the melting point as 
shown in Figure 7.  
 
 
 
Figure 7: DSC thermogram of optimized batch of solid dispersion 
 
5) X-ray diffraction studies 
The X-ray diffraction studies of optimized solid 
dispersion is shown in figure 8 and reduced peak height 
area in the diffractogram which  indicates that the 
change in the  nature of drug from crystalline to 
amorphous form. 
 
 
Figure 8: XRD of optimized batch of solid dispersion 
 
6) SCANNING ELECTRON MICROSCOPY 
The SEM of optimized solid dispersion shows irregular 
in shape and particles that indicate the change occur in 
the nature of the solid dispersion from crystalline to 
amorphous form as shown in the given Figures 9 at 
different magnifications. 
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Figure 9: SEM of Optimized Batch of solid dispersion at different magnifications 
Characterization parameters of prepared blend dosage form 
Table 5: Blend Characteristics of Tablet dosage form 
Parameters Observed Values 
Carr
”
s index (%) 11.6 
Angle of repose (
o
) 25 
Bulk Density (g/cc) 0.7 
Data Expressed as mean ± S.D (n=3) 
Evaluation Parameters of Tablet dosage form 
Table 6: Characterization Parameters of Optimized batch of Tablet Dosage form 
S.no Hardness 
(kg/cm) 
Wt. Variation 
(mg) 
Disintegration Time 
(min) 
Drug Content 
(%) 
Percent Yield (%) 
1 4.5+0.096 101.1+1.123 6.22 99.12+0.168 76.25±0.263 
2 4.1+0.049 100.3+1.068 6 98.62+0.268 78.26±0.169 
3 4.3+0.169 100.8+1.268 7 .46 99.33+0.144 81.65±0.259 
4 4.2+1.026 99.1+2.569 7 97.12+0.206 75.66±0.305 
5 4.4+0.059 100.7+1.546 6 .30 95.26+0.119 79.55±0.336 
6 4.7+0.076 100.6+2.056 6. 50 98.74+0.205 80.99±0.289 
7 4.6+0.088 101.0+1.359 7.16 99.65+0.116 81.45±0.178 
8 4.5+0.156 100.3+2.088 6 98.06+0.149 79.84±0.166 
9 4.2+0.169 101.8+1.444 7.19 99.84+0.256 76.45±0.246 
10 3.8+0.094 102.2+2.009 6 97.36+0.325 82.11±0.209 
Data Expressed as mean ± S.D (n=3) 
 
Figure 10: In vitro drug release data of Tablets Dosage 
form (%drug released vs. time) 
 
Figure 11: % DE60 of Tablet Dosage form
 
STABILITY TESTING OF THE TABLET DOSAGE FORM 
Dissolution Data after Stability 
 
Figure 12: In vitro drug release profile of Tablets Dosage 
form (%drug released vs. time) after stability studies 
 
 
Figure 13: In vitro dissolution efficiency of Tablet 
Dosage form after stability studies
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The stability studies values similar with the similarity 
factor and the values lie between 50-100 with the similar 
dissolution data that indicates stability of the tablet 
dosage form and shelf life of the product.  
CONCLUSION   
One of the pharmaceutical strategies to improve the oral 
bioavailability, solubility and dissolution is the 
formulation of solid dispersions. Solid dispersions in 
water-soluble carriers are regarded as highly effective 
means of increasing the dissolution rate which in turn 
enhances bioavailability of various drugs. Solid 
dispersions increase the solubility of drug due to the 
conversion of the drug’s crystal lattice into amorphous 
form, decrease in the particle size and increase in 
wettability caused by hydrophilic polymer. 
Rosuvastatin calcium tablets were successfully prepared 
in this study for enhanced solubility of the drug. For this 
purpose model drug used should be water insoluble i.e. 
Rosuvastatin Calcium (lipid lowering agent). The drug 
was used due to its poor aqueous solubility and low 
dissolution rate (BCS class II),  and prepared solid 
dispersions of Rosuvastatin Calcium that enhances the 
dissolution profile of  poorly water-soluble drug by using 
different hydrophilic carriers. 
Current study suggests the suitability of HPMC 
(hydroxypropylmethylcellulose) and EC (Ethyl cellulose) 
as a carrier for solid dispersions. Solid dispersions 
exhibited higher dissolution rates than those of physical 
mixtures and drug alone which is possibly due to increase 
in drug wettability caused by polymer used as carriers. 
Both HPMC and EC were used as carriers, used in 
different combinations by kneading method and 
optimized batch selected and solid dispersion of 
combination of both polymers are further characterized 
for FTIR, DSC, XRD, SEM and in vitro dissolution 
studies and then finally formulated into tablet dosage 
form. 
Rosuvastatin calcium tablets prepared by wet granulation 
method were evaluated with different parameters such as 
weight variation, hardness, friability, disintegration test 
and in vitro dissolution tests and determine that increase 
in the solubility and dissolution rate of the tablet dosage 
form and stability studies was performed on the prepared 
tablet dosage form and there is no liquification, 
discoloration, clump formation and no change in the 
dissolution rate of the tablet dosage form. There is no 
remarkable change occur in the tablet dosage form before 
and after stability studies. 
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